Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
AT-1965 by Alyssum Therapeutics for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
AT-1965 is under clinical development by Alyssum Therapeutics and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...
Data Insights
AT-1965 by Alyssum Therapeutics for Solid Tumor: Likelihood of Approval
AT-1965 is under clinical development by Alyssum Therapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase...